Crizotinib is a drug being developed by Pfizer to treat lung cancer, particularly non–small cell lung carcinoma that most frequently affects younger nonsmokers or former light smokers. Its mode of action is to inhibit the enzyme anaplastic lymphoma kinase (ALK). In a recent Phase I/II trial, crizotinib performed exceptionally well, and a Phase III trial is under way.
Learn more about this molecule from CAS, the most authoritative and comprehensive source for chemical information.
Stay Ahead of the Chemistry Curve
Learn how ACS can help you stay ahead in the world of chemistry.